NAALADL2

Summary

NAALADL2 (N-acetylated alpha-linked acidic dipeptidase like 2, HGNC:23219) is a protein-coding gene on chromosome 3q26.31, encoding Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 (Q58DX5). May be catalytically inactive.

Predicted to act upstream of or within response to bacterium. Located in nucleoplasm.

Source: NCBI Gene 254827 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 177 total — 1 likely-pathogenic
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_207015

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23219
Approved symbol	NAALADL2
Name	N-acetylated alpha-linked acidic dipeptidase like 2
Location	3q26.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000177694
Ensembl biotype	protein_coding
OMIM	608806
Entrez	254827

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding_CDS_not_defined, 2 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000414826, ENST00000434257, ENST00000454872, ENST00000473253, ENST00000478624, ENST00000481679, ENST00000482228, ENST00000485853, ENST00000489299, ENST00000489729, ENST00000491329, ENST00000495900

RefSeq mRNA: 1 — MANE Select: NM_207015 NM_207015

CCDS: CCDS46960

Canonical transcript exons

ENST00000454872 — 14 exons

Exon	Start	End
ENSE00001431711	175737306	175737399
ENSE00001434155	175755220	175755418
ENSE00001694236	174859334	174859450
ENSE00003466642	175324175	175324325
ENSE00003472529	175471639	175471758
ENSE00003513222	175576041	175576187
ENSE00003534674	175627291	175627386
ENSE00003539606	175256411	175256530
ENSE00003582619	175233931	175234204
ENSE00003618219	175466979	175467184
ENSE00003634427	175096790	175097291
ENSE00003660982	175463401	175463493
ENSE00003674142	175447229	175447372
ENSE00003767036	175803005	175810548

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 93.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4573 / max 152.7241, expressed in 1375 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
39870	4.2431	1310
39873	1.0923	206
39869	0.6438	380
39875	0.3963	127
39874	0.0818	47

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	93.87	gold quality
colonic epithelium	UBERON:0000397	82.32	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.87	gold quality
sural nerve	UBERON:0015488	79.98	gold quality
tendon	UBERON:0000043	79.66	gold quality
gall bladder	UBERON:0002110	79.42	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.10	gold quality
stromal cell of endometrium	CL:0002255	78.84	gold quality
ventricular zone	UBERON:0003053	77.50	gold quality
smooth muscle tissue	UBERON:0001135	76.69	gold quality
adrenal tissue	UBERON:0018303	76.04	gold quality
popliteal artery	UBERON:0002250	75.67	gold quality
tibial artery	UBERON:0007610	75.64	gold quality
descending thoracic aorta	UBERON:0002345	75.63	gold quality
aorta	UBERON:0000947	75.07	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	74.95	gold quality
left testis	UBERON:0004533	74.84	gold quality
right testis	UBERON:0004534	74.67	gold quality
thoracic aorta	UBERON:0001515	74.66	gold quality
ascending aorta	UBERON:0001496	74.61	gold quality
rectum	UBERON:0001052	74.51	gold quality
tibial nerve	UBERON:0001323	74.15	gold quality
ganglionic eminence	UBERON:0004023	74.08	gold quality
minor salivary gland	UBERON:0001830	73.95	gold quality
right coronary artery	UBERON:0001625	73.94	gold quality
islet of Langerhans	UBERON:0000006	73.92	gold quality
testis	UBERON:0000473	73.55	gold quality
endocervix	UBERON:0000458	72.96	gold quality
saliva-secreting gland	UBERON:0001044	72.95	gold quality
hindlimb stylopod muscle	UBERON:0004252	72.90	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	2415.07
E-CURD-119	yes	43.10
E-HCAD-10	yes	18.27
E-ANND-3	yes	8.26

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

224 targeting NAALADL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AA	99.96	70.64	3753

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 2)

• Data suggest that changes in expression of N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2) can impact upon a number of pro-oncogenic pathways and processes, making it a useful biomarker for both diagnosis and prognosis. (PMID:24240687)
• GWAS showed intestinal Behcet’s disease-specific associations with YIPF7 gene locus rs6838327. Down-regulation of YIPF7 expression was associated with exacerbating intestinal inflammatory responses both in vitro and in vivo. (PMID:28045058)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Naaladl2	ENSMUSG00000102758
rattus_norvegicus	Naaladl2	ENSRNOG00000065021

Paralogs (5): TFRC (ENSG00000072274), NAALAD2 (ENSG00000077616), FOLH1 (ENSG00000086205), TFR2 (ENSG00000106327), NAALADL1 (ENSG00000168060)

Protein

Protein identifiers

Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 — Q58DX5 (reviewed: Q58DX5)

All UniProt accessions (3): Q58DX5, C9JQ86, Q6H9J7

UniProt curated annotations — full annotation on UniProt →

Function. May be catalytically inactive.

Subcellular location. Membrane.

Tissue specificity. Expressed at higher level in kidney and placenta. In embryo, it is mainly confined to duodenal and stomach endoderm, mesonephros, metanephros and pancreas.

Miscellaneous. The gene maps to 3q26.31, a region associated with Cornelia de Lange syndrome. However, PubMed:15168106 failed to identify specific mutations in a panel of DNA samples from patients with Cornelia de Lange syndrome.

Similarity. Belongs to the peptidase M28 family. M28B subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q58DX5-1	1	yes
Q58DX5-2	2

RefSeq proteins (1): NP_996898* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007484	Peptidase_M28	Domain
IPR036757	TFR-like_dimer_dom_sf	Homologous_superfamily
IPR039373	Peptidase_M28B	Family
IPR046450	PA_dom_sf	Homologous_superfamily

Pfam: PF04389

UniProt features (19 total): sequence variant 6, glycosylation site 4, splice variant 3, topological domain 2, chain 1, transmembrane region 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q58DX5-F1	78.78	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 92

Glycosylation sites (4): 295, 373, 534, 759

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 128 (showing top): chr3q26, NKX62_Q2, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, IRF_Q6, TATA_C, HNF1_C, FREAC4_01, RYTTCCTG_ETS2_B, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, XU_GH1_AUTOCRINE_TARGETS_DN, ATGTTTC_MIR494, TGGAAA_NFAT_Q4_01, TAATTA_CHX10_01, GOBP_RESPONSE_TO_BACTERIUM, STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_DN

GO Biological Process (1): response to bacterium (GO:0009617)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleoplasm (GO:0005654), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
response to other organism	1
binding	1
nuclear lumen	1

Protein interactions and networks

STRING

894 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAALADL2	NIPBL	Q6KC79	716
NAALADL2	SMC1A	Q14683	640
NAALADL2	PAPPA	Q13219	588
NAALADL2	SMC3	Q9UQE7	587
NAALADL2	CDH13	P55290	569
NAALADL2	LNX1	Q8TBB1	558
NAALADL2	TCP1	P17987	542
NAALADL2	TAFA2	Q8N3H0	525
NAALADL2	ZFHX3	Q15911	525
NAALADL2	ITPKC	Q96DU7	494
NAALADL2	CSMD1	Q96PZ7	472
NAALADL2	KBTBD12	Q3ZCT8	465
NAALADL2	PPP1R14C	Q8TAE6	464
NAALADL2	YIPF7	Q8N8F6	461
NAALADL2	TMEM117	Q9H0C3	460

IntAct

20 interactions, top by confidence:

A	B	Type	Score
NAALADL2	GPR25	psi-mi:“MI:0915”(physical association)	0.560
GRM2	NAALADL2	psi-mi:“MI:0915”(physical association)	0.560
NAALADL2	LAPTM4B	psi-mi:“MI:0915”(physical association)	0.560
SLC30A3	NAALADL2	psi-mi:“MI:0915”(physical association)	0.560
ITM2B	NAALADL2	psi-mi:“MI:0915”(physical association)	0.560
NAALADL2	GRM2	psi-mi:“MI:0915”(physical association)	0.560
NAALADL2	SLC30A3	psi-mi:“MI:0915”(physical association)	0.560
GPR25	NAALADL2	psi-mi:“MI:0915”(physical association)	0.560
NAALADL2	ITM2B	psi-mi:“MI:0915”(physical association)	0.560
NAALADL2		psi-mi:“MI:0915”(physical association)	0.370
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
NAALADL2	IGSF3	psi-mi:“MI:0914”(association)	0.350

BioGRID (34): NAALADL2 (Two-hybrid), NAALADL2 (Two-hybrid), NAALADL2 (Two-hybrid), NAALADL2 (Two-hybrid), NAALADL2 (Two-hybrid), SCAP (Affinity Capture-MS), KLC2 (Affinity Capture-MS), NAALAD2 (Affinity Capture-MS), KCTD17 (Affinity Capture-MS), IGSF3 (Affinity Capture-MS), ERBB2 (Affinity Capture-MS), KCNJ8 (Affinity Capture-MS), CELSR2 (Affinity Capture-MS), SCARB2 (Affinity Capture-MS), HLA-DRB1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1S4FGH1, A0A7H0DN13, A4KX74, A4KX75, A8WQV9, G5EBL2, G5EBY8, G5ED05, G5ED65, G5EGA9, H2KZ72, H2KZM6, H2KZU7, I1FQB6, O14138, O45201, O45879, P12393, P13731, P16708, P18384, P18475, P20532, P21814, P33831, P34751, P41361, P46201, P46202, P46557, P54631, Q09219, Q09245, Q09271, Q0E8C8, Q17405, Q17678, Q18143, Q2KJH6, Q58DX5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

177 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	140
Likely benign	11
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
694264	GRCh37/hg19 3q26.31-26.32(chr3:175507453-177095072)	Likely pathogenic

SpliceAI

1644 predictions. Top by Δscore:

Variant	Effect	Δscore
3:175077860:G:GT	donor_gain	1.0000
3:175096785:CACAG:C	acceptor_loss	1.0000
3:175096788:AGG:A	acceptor_loss	1.0000
3:174963576:T:G	acceptor_gain	0.9900
3:175053540:TTTC:T	donor_gain	0.9900
3:175077889:A:T	donor_gain	0.9900
3:175096788:A:AG	acceptor_gain	0.9900
3:175096788:AG:A	acceptor_gain	0.9900
3:175096789:G:GA	acceptor_gain	0.9900
3:175096789:GG:G	acceptor_gain	0.9900
3:175096789:GGT:G	acceptor_gain	0.9900
3:175096789:GGTA:G	acceptor_gain	0.9900
3:175096789:GGTAA:G	acceptor_gain	0.9900
3:175077906:G:GT	donor_gain	0.9800
3:175096780:A:AG	acceptor_gain	0.9800
3:175096786:A:AG	acceptor_gain	0.9800
3:175096786:ACAG:A	acceptor_gain	0.9800
3:175096787:C:G	acceptor_gain	0.9800
3:175097287:TTCAG:T	donor_loss	0.9700
3:175097288:TCAGG:T	donor_loss	0.9700
3:175097290:AGGTA:A	donor_loss	0.9700
3:175097291:GGTA:G	donor_loss	0.9700
3:175097292:GTAG:G	donor_loss	0.9700
3:175097293:T:A	donor_loss	0.9700
3:175053534:A:G	donor_gain	0.9600
3:175053541:TTCA:T	donor_gain	0.9500
3:175029304:AG:A	donor_gain	0.9400
3:175096781:T:G	acceptor_gain	0.9400
3:174919491:TTC:T	donor_gain	0.9300
3:174951063:A:AG	donor_gain	0.9300

AlphaMissense

5238 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:175467117:G:C	R489P	0.994
3:175233995:T:A	W204R	0.988
3:175233995:T:C	W204R	0.988
3:175256493:C:A	A301E	0.984
3:175471739:T:C	L545P	0.984
3:175467137:T:A	W496R	0.983
3:175467137:T:C	W496R	0.983
3:175755364:T:C	L712P	0.983
3:175755352:T:C	L708P	0.979
3:175755356:T:A	N709K	0.979
3:175755356:T:G	N709K	0.979
3:175755265:T:C	L679P	0.978
3:175256502:A:T	K304I	0.977
3:175466982:G:C	R444P	0.976
3:175463467:G:A	G434E	0.972
3:175466999:A:C	S450R	0.972
3:175467001:C:A	S450R	0.972
3:175467001:C:G	S450R	0.972
3:175256503:A:C	K304N	0.971
3:175256503:A:T	K304N	0.971
3:175324199:T:C	F322L	0.968
3:175324201:T:A	F322L	0.968
3:175324201:T:G	F322L	0.968
3:175467176:T:A	W509R	0.967
3:175467176:T:C	W509R	0.967
3:175755355:A:T	N709I	0.967
3:175097035:T:C	F97L	0.966
3:175097037:C:A	F97L	0.966
3:175097037:C:G	F97L	0.966
3:175256499:T:C	L303P	0.966

dbSNP variants (sampled 300 via entrez): RS1000000179 (3:175402745 C>G,T), RS1000000785 (3:175470378 A>G), RS1000001543 (3:175218883 G>A), RS1000002864 (3:175627751 A>G,T), RS1000004025 (3:175239786 G>A,T), RS1000007970 (3:175787235 TC>T), RS1000016058 (3:174786400 G>A), RS1000018631 (3:174844152 C>T), RS1000030402 (3:175011618 C>G,T), RS1000032223 (3:174734987 C>G,T), RS1000032672 (3:175432948 T>C), RS1000033329 (3:175220228 G>A), RS1000035233 (3:174460142 A>C), RS1000035695 (3:175312914 G>A), RS1000035935 (3:175470645 G>A)

Disease associations

OMIM: gene MIM:608806 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST000314_2	Kawasaki disease	1.000000e-06
GCST000996_23	Systemic lupus erythematosus	8.000000e-06
GCST001822_5	Metabolite levels (MHPG)	1.000000e-06
GCST001885_8	Height	8.000000e-06
GCST002053_4	Sleep duration	3.000000e-06
GCST002886_2	Prostate cancer aggressiveness	4.000000e-08
GCST003126_1	Influenza A (H1N1) severity	6.000000e-07
GCST003130_1	Autism spectrum disorder	4.000000e-06
GCST003771_10	Loneliness	4.000000e-06
GCST004370_2	Deep ovarian and/or rectovaginal disease with dense adhesions	1.000000e-07
GCST005439_3	Response to alcohol consumption (flushing response)	4.000000e-06
GCST006087_20	Familial lung adenocarcinoma	3.000000e-06
GCST007326_52	Number of sexual partners	2.000000e-09
GCST007393_2	Mitochondrial DNA copy number	2.000000e-08
GCST007473_13	Rapid automatized naming of pictures	2.000000e-06
GCST007673_3	3-month functional outcome in ischaemic stroke (modified Rankin score)	3.000000e-07
GCST009550_2	Priapism in sickle cell disease	3.000000e-08
GCST010172_2	Idiopathic downbeat nystagmus	9.000000e-06
GCST010923_12	Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)	9.000000e-06
GCST011742_45	Triglyceride levels in HIV infection	3.000000e-06
GCST012490_93	Femur bone mineral density x serum urate levels interaction	4.000000e-10

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0005133	MHPG measurement
EFO:0006999	cancer aggressiveness measurement
EFO:0007000	Gleason score measurement
EFO:0007743	influenza A severity measurement
EFO:0007865	loneliness measurement
EFO:0006953	family history of lung cancer
EFO:0006312	mitochondrial DNA measurement
EFO:0005301	reading and spelling ability
EFO:0009603	stroke outcome severity measurement
EFO:0004352	mortality
EFO:0007766	response to beta blocker
EFO:0004530	triglyceride measurement
EFO:0004531	urate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	3
Aflatoxin B1	decreases expression, decreases methylation	3
lasiocarpine	decreases expression	2
methyleugenol	decreases expression	2
N-Nitrosopyrrolidine	decreases expression	2
Tobacco Smoke Pollution	decreases methylation, affects expression	2
Valproic Acid	increases methylation	2
aristolochic acid I	decreases expression	1
aflatoxin B2	increases methylation	1
rofecoxib	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Phthalic Acids	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Palmitic Acid	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders